PharmiWeb.com - Global Pharma News & Resources

General - Press Releases

Date Title Company
04-Jun-2021 ADC Therapeutics Presents Updated Clinical Data at 2021 ASCO Annual Meeting Businesswire
04-Jun-2021 First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s) Businesswire
04-Jun-2021 Carbon Health Acquires CGM-Enabled Virtual Diabetes Clinic Steady Health, Expands Executive Bench to Accelerate Next Stage of Omnichannel Growth Businesswire
04-Jun-2021 Insights on the Eggshell Membrane Global Market to 2028 - by Type, Application and Region - ResearchAndMarkets.com Businesswire
04-Jun-2021 Global DNA & RNA Banking Services Market (2021 to 2028) - Share, Size, Trends and Industry Analysis Report - ResearchAndMarkets.com Businesswire
04-Jun-2021 Five Day Online Medical Device Summer School: From Concept to CE Marking Training Course, July 5th-9th, 2021 - ResearchAndMarkets.com Businesswire
04-Jun-2021 Tachyon Announces Presentations at the ASCO Annual Meeting Businesswire
04-Jun-2021 Diaceutics to Release Breakthrough Data on COVID-19 Impact on Cancer at 2021 American Society of Clinical Oncology (ASCO) Meeting Businesswire
04-Jun-2021 Global Corporate Reputation of Pharma in 2020 During the Covid Pandemic: Opinions of 1,920 Patient Groups on the Performance of the Pharmaceutical Industry - ResearchAndMarkets.com Businesswire
04-Jun-2021 Puma Biotechnology Presents Data from the EGFR Exon 18-mutant NSCLC Cohort of the Phase II SUMMIT Trial at the 2021 ASCO Annual Meeting Businesswire
04-Jun-2021 Puma Biotechnology Presents Data Comparing Findings from the Phase II CONTROL Trial with the Neratinib Arm of the Phase III ExteNET Trial at the ASCO 2021 Annual Meeting Businesswire
04-Jun-2021 Puma Biotechnology Presents Data from the Phase III ExteNET Trial in Early Stage HER2-Positive Breast Cancer Patients at the Virtual 2021 ASCO Annual Meeting Businesswire
04-Jun-2021 Exelixis Announces Consistent Efficacy Benefits Across Subgroups of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-line Treatment for Patients with Advanced Renal Cell Carcinoma Businesswire
04-Jun-2021 Magenta Therapeutics Announces Additional Preliminary Positive Results from Ongoing Phase 2 Clinical Trial of MGTA-145 and Plerixafor in Patients with Multiple Myeloma at the American Society of Clinical Oncology (ASCO) Annual Meeting Businesswire
04-Jun-2021 Exelixis Announces Quality-Adjusted Survival Benefit Demonstrated in Analysis of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) in Patients with Previously Untreated Advanced Renal Cell Carcinoma Businesswire
04-Jun-2021 BeiGene Presents Clinical Data from Two Phase 2 Trials of Pamiparib at the 2021 ASCO Annual Meeting Businesswire
04-Jun-2021 BeiGene Presents Clinical Data from Two Pivotal Trials of Tislelizumab at the 2021 ASCO Annual Meeting Businesswire
04-Jun-2021 Lyvgen Biopharma Presents Clinical Trial Data of CD137/4-1BB Agonistic Antibody LVGN6051 at the 2021 ASCO Annual Meeting Businesswire
04-Jun-2021 Exelixis Announces Positive Phase 2 Results for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma at ASCO 2021 Businesswire
04-Jun-2021 Global Psychedelic Drugs Market Research Report 2021: Analysis by Drug, Route of Administration, Distribution Channel, Pipeline Drugs and Forecast to 2026 - ResearchAndMarkets.com Businesswire